From Financialpost · · 1m 20s
Conexeu Sciences Raises $5M for FDA Submission
Conexeu Sciences closes $5M private placement to fund FDA 510(k) submission by Q1 2027.
In brief
Conexeu Sciences closes $5M private placement to fund FDA 510(k) submission by Q1 2027. Conexeu Sciences raised $5 million through private placement to support FDA 510(k) submission for its wound care device candidate by Q1 2027. Originally reported by Financialpost.
Conexeu Sciences Announces $5M Private Placement
Conexeu Sciences Inc. closed a private placement of approximately $5 million led by existing shareholders, management, and directors.
Escrowed Funds for Stockholder Approval
The $250,000 from management and directors is held in escrow pending stockholder approval under Nasdaq Listing Rule 5635(c).
Private Placement Terms
The Private Placement consists of 1,666,667 units at $3.00 per unit, each unit includes one share and one warrant to purchase one share at $3.00.
Special Warrants for Canadian Subscribers
For Canadian subscribers, the Company issued special warrants at $3.00 each, convertible into one share and one warrant upon British Columbia Securities Commission approval or February 16, 2027.
Leadership Team
The Private Placement was led by CEO Miles Harrison and Chief Commercial Officer David Bogart.
Funding Purpose
Conexeu plans to use net proceeds for manufacturing scale-up, regulatory testing, and preclinical work toward FDA 510(k) submission by Q1 2027.
Recent Progress
The financing follows Conexeu's Oct. 6, 2026 program update showing scaled-up CXU material met specifications and on track for Q1 2027 FDA submission.
At a glance
Conexeu Sciences raised $5 million through private placement to support FDA 510(k) submission for its wound care device candidate by Q1 2027.
